12 Aug 2013
ERGOMED Group and CEL-SCI Sign Co-Development Agreement for Multikine in Head and Neck Cancer

Ergomed Clinical Research Ltd. (“ERGOMED Group ”) today announced the signing of a co-development and revenue sharing agreement with CEL-SCI Corporation  (NYSE MKT: CVM) for Multikine in head and neck cancer. Under the agreement ERGOMED Group will work with CEL-SCI conducting a multicenter, multinational, randomized Phase 3 trial with Multikine in head and neck cancer.